Recent Company News

• 08:04 AM ET Jan 13, 2026
  

  Evaxion notes 2026 milestones and maintains cash runway into 2H27 ($5.18, 0.00)

• 08:00 AM ET Jan 07, 2026
  

  Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

• 07:05 AM ET Dec 19, 2025
  

  Evaxion provides update on EVX-B2, says Merck will not exercise its option for the vaccine candidate ($5.75, 0.00)

• 09:15 AM ET Dec 11, 2025
  

  Transcript Intelligence: Evaxion AS at Sidoti Year End Virtual Investor Conference ($6.37, 0.00)

• 08:26 AM ET Dec 08, 2025
  

  StreetAccount Summary - US Pre-market trading

• 03:01 PM ET Dec 06, 2025
  

  Evaxion AS announces new data for EVX-04 indicating it triggers strong specific T-cell responses and effectively prevents tumor growth in preclinical models ($5.25, 0.00)

• 08:02 AM ET Nov 20, 2025
  

  Evaxion announces data for lead antigens in cytomegalovirus vaccine program EVX-V1 ($4.88, 0.00)

• 05:16 PM ET Nov 07, 2025
  

  Evaxion Biotech presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 ($6.38, 0.00)

• 07:43 AM ET Nov 06, 2025
  

  Evaxion Biotech reports Q3 EPS $0.01 vs FactSet $0.20 [2 est, ($0.01)-0.40] ($5.66, 0.00)

• 09:11 AM ET Nov 03, 2025
  

  Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate ($5.75, 0.00)